Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Voltage-dependent T-type calcium channel subunit alpha-1G, commonly known as Cav3.1, is a pore-forming protein that facilitates the influx of calcium ions into cells at low membrane potentials. It is a critical regulator of neuronal excitability, particularly within the thalamocortical circuit, where it supports rhythmic burst firing and oscillatory activity. In addition to its role in the central nervous system, Cav3.1 contributes to cardiac pacemaking in the sinoatrial and atrioventricular nodes. Its unique low-voltage activation threshold allows it to modulate cellular responses near the resting membrane potential. Dysregulation of Cav3.1 is linked to several neurological conditions, most notably childhood absence epilepsy and essential tremor, where aberrant burst firing occurs. Mutations in the encoding gene, CACNA1G, have been identified as the cause of spinocerebellar ataxia type 42 (SCA42). Furthermore, altered expression of this channel has been observed in various cancers, such as prostate and colorectal cancer, where it may influence cell proliferation or act as a tumor suppressor. Therapeutic targeting of Cav3.1 involves small-molecule inhibitors, including traditional antiepileptics like ethosuximide and novel selective blockers like suvecaltamide, which are being investigated for movement disorders.
Blockade of T-type calcium currents, inhibition of low-threshold calcium spikes, and suppression of neuronal burst firing.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent T-type calcium channel subunit alpha-1G (Cav3.1) (Cav3.1).